Including debt, the deal, which is expected to close in the third quarter of this year, is valued around $5.2 billion.
Although Anacor currently doesn’t have any products on the market, it has the rights to Kerydin, a treatment for toenail fungus, according to the report. Pfizer believes Kerydin and Anacor’s other offerings would balance Pfizer’s inflammation and immunology products.
More articles on transaction and valuation issues:
Texas Health Resources casts highest bid for bankrupt Fort Worth hospital
Following collapse of Novant, Memorial partnership, HCA enters with offer
HCA to buy yet-to-open Texas hospital for $115M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.